OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization). The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has state-of-the-art manufacturing facilities approved by global regulatory authorities, enabling it to deliver world-class development and manufacturing capabilities with precision, scale, and reliability. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. Its comprehensive solutions span across platforms and therapeutic modalities, including Biologics, Drug-device combinations, Complex Injectables, and Oral Technologies.

Business area of the company

OneSource Specialty Pharma is evolved into an integrated, multimodal specialty pharmaceutical CDMO. The company specialises in offering end-to-end solutions across biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatin capsules).

Awards

2024-25

• OneSource received the Sustainable Organisation Award 2025 at the 5th Sustainability Summit hosted by UBS Forums on June 11, 2025 in Gurgaon.
• Received ESG award in gold category from OHSSAI Foundation.
• Received best safety award in gold category from OHSSAI Foundation.

Milestones

• 1990: Incorporation of the company as Strides Pharmaceutical Private Limited.
• 1995: New sterile manufacturing facility in Bangalore commenced production.
• 1998: Commissioned soft gelatin capsule plant at KBS Gardens, Bangalore.
• 2007: First USFDA approval for Penicillin site.
• 2010: Rebranded specialty (injection) division as Agila Specialties Private Limited.
• 2014: Biotech business re-branded as ‘Stelis Biopharma’.
• 2020: Re-entered injectable business with SteriScience.
• 2022: Drug Product (DP) manufacturing at Unit-2 of Stelis Biopharma got FDA approval.
• 2023: Strides Pharma, Steriscience and Stelis Biopharma (now known as OneSource) agreed the proposed demerger to merge Strides’ softgel business, SteriScience Injectables, and Stelis Biopharma into OneSource with effect from April 01, 2024.
• 2024: Received ‘No objection’ from NSE and ‘No adverse observations’ from BSE and SEBI on May 21, 2024.
• 2024: Shareholders and secured creditors of all 3 companies approved the scheme at NCLT-supervised meetings on September 10, 2024.
• 2024: OneSource received equity commitments of Rs 8,010 million ($95 million) from marquee investors at a pre-money valuation of $1.65 billion in October 16, 2024.
• 2024: NCLT (Mumbai) sanctioned the Scheme of Arrangement, formalising creation of OneSource on November 19, 2024.
• 2024: Successfully completed fundraise of Rs 8,010 million, with equity shares allotted to leading
• domestic and international investors on November 25, 2024. 
• 2024: OneSource shares allotted purusant to the Scheme: 1 share (Rs 1 each) for every 2 shares (Rs 10 each) held by Strides shareholders; 1,515 shares Rs 1 each) for every 1 share Rs 10 each) held by SteriScience shareholders on December 10, 2024.
• 2025: Final listing and trading approval received from the NSE and BSE on January 22, 2025.
• 2025: OneSource commenced trading on the NSE and BSE on January 24, 2025.
• 2025: Secured regulatory approval from ANVISA for the flagship manufacturing facility.
• 2025: Joined the United Nations Global Compact (UNGC), reaffirming commitment to sustainability, social responsibility, and strong governance.
• 2025: Credit rating upgraded to A-; Outlook: Positive, from India Ratings & Research for bank facilities.
• 2025: Successfully maintained USFDA compliance at the flagship manufacturing facility.